» Articles » PMID: 30014505

Neurofilament Light: A Candidate Biomarker of Presymptomatic Amyotrophic Lateral Sclerosis and Phenoconversion

Overview
Journal Ann Neurol
Specialty Neurology
Date 2018 Jul 18
PMID 30014505
Citations 130
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate neurofilament light (NfL) as a biomarker of the presymptomatic phase of amyotrophic lateral sclerosis (ALS).

Methods: The study population includes 84 individuals at risk for developing ALS, 34 controls, 17 ALS patients, and 10 phenoconverters (at-risk individuals observed both before and after the emergence of clinically manifest disease). At-risk individuals are enrolled through Pre-Symptomatic Familial ALS (Pre-fALS), a longitudinal natural history and biomarker study of individuals who are carriers of any ALS-associated gene mutation (in SOD1, C9orf72, TARDBP, FUS, VCP, etc), but who, at the time of enrollment, demonstrated no clinical symptoms or signs (including electromyographic evidence) of manifest disease. NfL in serum and cerebrospinal fluid (CSF) were quantified using an electrochemiluminescence immunoassay.

Results: Serum and CSF NfL are substantially higher in ALS patients compared to controls and at-risk individuals and remain relatively stable over time. Among phenoconverters, however, NfL levels were elevated (ie, above the range observed in controls) as far back as ∼12 months preceding the emergence of the earliest clinical symptoms or signs of disease.

Interpretation: Serum (and CSF) NfL are informative biomarkers of presymptomatic ALS, providing a new tool to quantify presymptomatic disease progression and to potentially predict the timing of clinical phenoconversion. As such, quantification of NfL may aid the design and implementation of early therapeutic intervention for affected individuals and/or disease prevention trials for individuals at short-term risk of developing ALS. Ann Neurol 2018 Ann Neurol 2018;83:130-139.

Citing Articles

Metabolomic and Proteomic Profiling of Serum-Derived Extracellular Vesicles from Early-Stage Amyotrophic Lateral Sclerosis Patients.

Al Ojaimi Y, Vallet N, Dangoumau A, Lanznaster D, Bruno C, Lefevre A J Mol Neurosci. 2025; 75(1):21.

PMID: 39954028 DOI: 10.1007/s12031-025-02315-w.


Blood level of neurofilament light chain as a biomarker for neurological disorders.

Turner M, Thompson A, Teunissen C BMJ Med. 2025; 4(1):e000958.

PMID: 39845125 PMC: 11749884. DOI: 10.1136/bmjmed-2024-000958.


Evaluation of a biomarker for amyotrophic lateral sclerosis derived from a hypomethylated DNA signature of human motor neurons.

Harvey C, Nowak A, Zhang S, Moll T, Weimer A, Barcons A BMC Med Genomics. 2025; 18(1):10.

PMID: 39810183 PMC: 11734586. DOI: 10.1186/s12920-025-02084-w.


Evaluation of a biomarker for amyotrophic lateral sclerosis derived from a hypomethylated DNA signature of human motor neurons.

Harvey C, Nowak A, Zhang S, Moll T, Weimer A, Barcons A Res Sq. 2024; .

PMID: 39649175 PMC: 11623773. DOI: 10.21203/rs.3.rs-5397445/v1.


Clinical features and progress in diagnosis and treatment of amyotrophic lateral sclerosis.

Yuan D, Jiang S, Xu R Ann Med. 2024; 56(1):2399962.

PMID: 39624969 PMC: 11616751. DOI: 10.1080/07853890.2024.2399962.


References
1.
Benatar M, Stanislaw C, Reyes E, Hussain S, Cooley A, Fernandez M . Presymptomatic ALS genetic counseling and testing: Experience and recommendations. Neurology. 2016; 86(24):2295-302. PMC: 4909562. DOI: 10.1212/WNL.0000000000002773. View

2.
Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen P . Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2015; 87(1):12-20. DOI: 10.1136/jnnp-2015-311387. View

3.
Mitchell J, Callagher P, Gardham J, Mitchell C, Dixon M, Addison-Jones R . Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)--a 20-year review: can we do better?. Amyotroph Lateral Scler. 2010; 11(6):537-41. DOI: 10.3109/17482968.2010.495158. View

4.
Weydt P, Oeckl P, Huss A, Muller K, Volk A, Kuhle J . Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2015; 79(1):152-8. DOI: 10.1002/ana.24552. View

5.
Andersen P, Al-Chalabi A . Clinical genetics of amyotrophic lateral sclerosis: what do we really know?. Nat Rev Neurol. 2011; 7(11):603-15. DOI: 10.1038/nrneurol.2011.150. View